JP5470653B2 - カルシウム受容体調節剤 - Google Patents
カルシウム受容体調節剤 Download PDFInfo
- Publication number
- JP5470653B2 JP5470653B2 JP2009534673A JP2009534673A JP5470653B2 JP 5470653 B2 JP5470653 B2 JP 5470653B2 JP 2009534673 A JP2009534673 A JP 2009534673A JP 2009534673 A JP2009534673 A JP 2009534673A JP 5470653 B2 JP5470653 B2 JP 5470653B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- chloro
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 title description 35
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 title description 35
- 229940075993 receptor modulator Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 172
- 125000000217 alkyl group Chemical group 0.000 claims description 98
- -1 Phenylmethyl (2-chloro-5-((((1R) -1-phenylethyl) amino) methyl) phenyl) carbamate Chemical compound 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 49
- 229920006395 saturated elastomer Polymers 0.000 claims description 42
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 35
- 230000015572 biosynthetic process Effects 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 206010012735 Diarrhoea Diseases 0.000 claims description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 125000001624 naphthyl group Chemical group 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 150000001412 amines Chemical class 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- BNMPIJWVMVNSRD-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NO1 BNMPIJWVMVNSRD-UHFFFAOYSA-N 0.000 claims description 10
- 208000005475 Vascular calcification Diseases 0.000 claims description 10
- KBOSIRPMGVGOEP-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carboxamide Chemical compound CC1=CC(C(N)=O)=NO1 KBOSIRPMGVGOEP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- CFQXUNOKFPCZRI-MRXNPFEDSA-N 2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]-n-(pyridin-2-ylmethyl)aniline Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NCC1=CC=CC=N1 CFQXUNOKFPCZRI-MRXNPFEDSA-N 0.000 claims description 5
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- MGWSZTWZXQFLIA-KWCCSABGSA-N n-[2-chloro-5-[1-[[(1r)-1-(3-chlorophenyl)ethyl]amino]ethyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(C)C(C=1)=CC=C(Cl)C=1NC(=O)C=1C=C(C)ON=1 MGWSZTWZXQFLIA-KWCCSABGSA-N 0.000 claims description 5
- YAXTYTCZFOQFTI-CYBMUJFWSA-N n-[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1C=C(C)ON=1 YAXTYTCZFOQFTI-CYBMUJFWSA-N 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- XSZGSKARTJPNTM-CQSZACIVSA-N 6-chloro-n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=C(Cl)N=C1 XSZGSKARTJPNTM-CQSZACIVSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- LTJLWSOJMLKKLI-MRXNPFEDSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-2-pyrrolidin-1-ylacetamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)CN1CCCC1 LTJLWSOJMLKKLI-MRXNPFEDSA-N 0.000 claims description 4
- FEVFRWGLLNXWOZ-MRXNPFEDSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-(dimethylamino)pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=C(N(C)C)N=C1 FEVFRWGLLNXWOZ-MRXNPFEDSA-N 0.000 claims description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- CRUKIGNTCYWOOO-MRXNPFEDSA-N 1-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-3-phenylurea Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)NC1=CC=CC=C1 CRUKIGNTCYWOOO-MRXNPFEDSA-N 0.000 claims description 3
- JNKXUEZTWJHDFB-QGZVFWFLSA-N 1-tert-butyl-n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-methylpyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1C=C(C)N(C(C)(C)C)N=1 JNKXUEZTWJHDFB-QGZVFWFLSA-N 0.000 claims description 3
- BRZNGIIVFRXONA-HXUWFJFHSA-N 6-(benzylamino)-n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(C=N1)=CC=C1NCC1=CC=CC=C1 BRZNGIIVFRXONA-HXUWFJFHSA-N 0.000 claims description 3
- CKIQSWWEOSBLJP-LJQANCHMSA-N 6-anilino-n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(C=N1)=CC=C1NC1=CC=CC=C1 CKIQSWWEOSBLJP-LJQANCHMSA-N 0.000 claims description 3
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- USDLOMUMYNLIKC-QGZVFWFLSA-N n-[2-chloro-5-[[[(1r)-1-naphthalen-1-ylethyl]amino]methyl]phenyl]pyridine-2-carboxamide Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CC=N1 USDLOMUMYNLIKC-QGZVFWFLSA-N 0.000 claims description 3
- FCLCKXFJHONGCY-CYBMUJFWSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=NO1 FCLCKXFJHONGCY-CYBMUJFWSA-N 0.000 claims description 3
- YJUSFFDKYWMYDD-CYBMUJFWSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-2,5-dimethyl-1,3-oxazole-4-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1N=C(C)OC=1C YJUSFFDKYWMYDD-CYBMUJFWSA-N 0.000 claims description 3
- CIIWQDQMSLOKDL-OAHLLOKOSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-2,5-dimethylpyrazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC(C)=NN1C CIIWQDQMSLOKDL-OAHLLOKOSA-N 0.000 claims description 3
- CSZVETMFJGADOZ-GOSISDBHSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-3-phenylpropanamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)CCC1=CC=CC=C1 CSZVETMFJGADOZ-GOSISDBHSA-N 0.000 claims description 3
- AZPYPPUUQUGDRI-GFCCVEGCSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1SN=NC=1C AZPYPPUUQUGDRI-GFCCVEGCSA-N 0.000 claims description 3
- OBVQBPDZJPIJBH-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-(2-methyl-1,3-thiazol-4-yl)-1,2-oxazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(=NO1)C=C1C1=CSC(C)=N1 OBVQBPDZJPIJBH-CQSZACIVSA-N 0.000 claims description 3
- IYOBQZNFVSOWDU-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1C=C(C)ON=1 IYOBQZNFVSOWDU-CQSZACIVSA-N 0.000 claims description 3
- XASVCRTUDCBQRB-QGZVFWFLSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(=NO1)C=C1C1=CC=CC=C1 XASVCRTUDCBQRB-QGZVFWFLSA-N 0.000 claims description 3
- HRPFICMCULRUFD-GOSISDBHSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-phenylthiophene-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(S1)=CC=C1C1=CC=CC=C1 HRPFICMCULRUFD-GOSISDBHSA-N 0.000 claims description 3
- QYURQIJGBNFSCB-QGZVFWFLSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-5-pyridin-2-ylthiophene-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(S1)=CC=C1C1=CC=CC=N1 QYURQIJGBNFSCB-QGZVFWFLSA-N 0.000 claims description 3
- UDCWJIZVKUOHIG-OAQYLSRUSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-(2-phenylethylamino)pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(C=N1)=CC=C1NCCC1=CC=CC=C1 UDCWJIZVKUOHIG-OAQYLSRUSA-N 0.000 claims description 3
- CUUDIUQBUVFDTN-OAHLLOKOSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-(methylamino)pyridine-3-carboxamide Chemical compound C1=NC(NC)=CC=C1C(=O)NC1=CC(CN[C@H](C)C=2C=CC=CC=2)=CC=C1Cl CUUDIUQBUVFDTN-OAHLLOKOSA-N 0.000 claims description 3
- BBYHKJFAPCLHIZ-GOSISDBHSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-[2-(dimethylamino)ethylamino]pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=C(NCCN(C)C)N=C1 BBYHKJFAPCLHIZ-GOSISDBHSA-N 0.000 claims description 3
- GLKIOOGLMRWYRK-GOSISDBHSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(C=N1)=CC=C1N1CCOCC1 GLKIOOGLMRWYRK-GOSISDBHSA-N 0.000 claims description 3
- HVTMSWHSQIHUBG-MRXNPFEDSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]benzamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CC=C1 HVTMSWHSQIHUBG-MRXNPFEDSA-N 0.000 claims description 3
- HADVVSRBDSHVLV-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]furan-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CO1 HADVVSRBDSHVLV-CQSZACIVSA-N 0.000 claims description 3
- SLBPHKGSJJETHF-OAHLLOKOSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CC=N1 SLBPHKGSJJETHF-OAHLLOKOSA-N 0.000 claims description 3
- ROMUAKQWHDCLLS-OAHLLOKOSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CN=C1 ROMUAKQWHDCLLS-OAHLLOKOSA-N 0.000 claims description 3
- ZEGDEFDDNJWXAK-OAHLLOKOSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]pyridine-4-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=NC=C1 ZEGDEFDDNJWXAK-OAHLLOKOSA-N 0.000 claims description 3
- MXDASJKRWFJTLM-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]thiophene-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C1=CC=CS1 MXDASJKRWFJTLM-CQSZACIVSA-N 0.000 claims description 3
- PJBWOVRUBAXTKZ-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]thiophene-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C=1C=CSC=1 PJBWOVRUBAXTKZ-CQSZACIVSA-N 0.000 claims description 3
- JVXALWDTZHBFEE-HXUWFJFHSA-N n-[2-methoxy-5-[[[(1r)-1-naphthalen-1-ylethyl]amino]methyl]phenyl]-n-methylbenzamide Chemical compound COC1=CC=C(CN[C@H](C)C=2C3=CC=CC=C3C=CC=2)C=C1N(C)C(=O)C1=CC=CC=C1 JVXALWDTZHBFEE-HXUWFJFHSA-N 0.000 claims description 3
- FDNBMPQORQHAAS-KRWDZBQOSA-N n-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenyl]-2-pyrrolidin-1-ylacetamide Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(NC(=O)CN3CCCC3)C=CC=2)=C1 FDNBMPQORQHAAS-KRWDZBQOSA-N 0.000 claims description 3
- MVRGUZHVJBVHOQ-HNNXBMFYSA-N n-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(NC(=O)C3=NOC(C)=C3)C=CC=2)=C1 MVRGUZHVJBVHOQ-HNNXBMFYSA-N 0.000 claims description 3
- NKZDAWCMPLNYAL-HNNXBMFYSA-N n-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenyl]thiophene-2-carboxamide Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(NC(=O)C=3SC=CC=3)C=CC=2)=C1 NKZDAWCMPLNYAL-HNNXBMFYSA-N 0.000 claims description 3
- MSDZMWIHZLIMIV-IBGZPJMESA-N n-[3-[[[(1s)-1-naphthalen-1-ylethyl]amino]methyl]phenyl]-2-pyrrolidin-1-ylacetamide Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1NC(=O)CN1CCCC1 MSDZMWIHZLIMIV-IBGZPJMESA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- ZHPYAAGDTXDRTL-LJQANCHMSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-6-(4-methylpiperazin-1-yl)pyridine-3-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1NC(=O)C(C=N1)=CC=C1N1CCN(C)CC1 ZHPYAAGDTXDRTL-LJQANCHMSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 193
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 134
- 235000019439 ethyl acetate Nutrition 0.000 description 89
- 239000000243 solution Substances 0.000 description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 239000011541 reaction mixture Substances 0.000 description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 50
- 238000001819 mass spectrum Methods 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 43
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 41
- 239000012267 brine Substances 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 40
- 229910002027 silica gel Inorganic materials 0.000 description 40
- 239000000203 mixture Substances 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 201000010099 disease Diseases 0.000 description 31
- 208000002551 irritable bowel syndrome Diseases 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 239000011575 calcium Substances 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 27
- 239000012230 colorless oil Substances 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 230000002092 calcimimetic effect Effects 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 102000003982 Parathyroid hormone Human genes 0.000 description 19
- 108090000445 Parathyroid hormone Proteins 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 19
- 239000000199 parathyroid hormone Substances 0.000 description 19
- 229960001319 parathyroid hormone Drugs 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 210000000557 podocyte Anatomy 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000003480 eluent Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 239000013058 crude material Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- DQEYVZASLGNODG-ZCFIWIBFSA-N (1r)-1-(3-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Cl)=C1 DQEYVZASLGNODG-ZCFIWIBFSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 238000010626 work up procedure Methods 0.000 description 9
- 229910001424 calcium ion Inorganic materials 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 230000000849 parathyroid Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- LEFJRKGYMOGVOA-OAHLLOKOSA-N (1r)-1-(3-chlorophenyl)-n-[(4-chloro-3-phenylsulfanylphenyl)methyl]ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1SC1=CC=CC=C1 LEFJRKGYMOGVOA-OAHLLOKOSA-N 0.000 description 6
- UPNODODZESFQEQ-SNVBAGLBSA-N (1r)-n-[(4-chloro-3-nitrophenyl)methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC1=CC=C(Cl)C([N+]([O-])=O)=C1 UPNODODZESFQEQ-SNVBAGLBSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 5
- DRIDBRVSJHRJOP-CQSZACIVSA-N (1r)-n-[(4-chloro-3-morpholin-4-ylsulfonylphenyl)methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1S(=O)(=O)N1CCOCC1 DRIDBRVSJHRJOP-CQSZACIVSA-N 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- DCQZHOAMZHRGQQ-SNVBAGLBSA-N 2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenol Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC1=CC=C(Cl)C(O)=C1 DCQZHOAMZHRGQQ-SNVBAGLBSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- CWTFIQPAWHQJER-OAHLLOKOSA-N (1r)-1-(3-chlorophenyl)-n-[(4-methoxy-3-morpholin-4-ylsulfonylphenyl)methyl]ethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)S(=O)(=O)N2CCOCC2)OC)=CC=CC(Cl)=C1 CWTFIQPAWHQJER-OAHLLOKOSA-N 0.000 description 4
- SHYNHFYYUCZJPH-AAFJCEBUSA-N (1r)-1-(3-chlorophenyl)-n-[[4-chloro-3-(1-pyridin-2-ylethoxy)phenyl]methyl]ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OC(C)C1=CC=CC=N1 SHYNHFYYUCZJPH-AAFJCEBUSA-N 0.000 description 4
- TVXUFSYRKZMTSB-OAHLLOKOSA-N (1r)-1-(3-fluorophenyl)-n-[(4-methoxy-3-pyrrolidin-1-ylphenyl)methyl]ethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)N2CCCC2)OC)=CC=CC(F)=C1 TVXUFSYRKZMTSB-OAHLLOKOSA-N 0.000 description 4
- LIWWLSJJRIOGTH-OAHLLOKOSA-N (1r)-n-[[3-(benzenesulfonyl)-4-chlorophenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1S(=O)(=O)C1=CC=CC=C1 LIWWLSJJRIOGTH-OAHLLOKOSA-N 0.000 description 4
- FNHSQSIDYVJAHC-MRXNPFEDSA-N (1r)-n-[[3-(benzimidazol-1-yl)-4-chlorophenyl]methyl]-1-phenylethanamine Chemical compound C1([C@H](NCC=2C=C(C(Cl)=CC=2)N2C3=CC=CC=C3N=C2)C)=CC=CC=C1 FNHSQSIDYVJAHC-MRXNPFEDSA-N 0.000 description 4
- GPFBWTUFZHDMRQ-CYBMUJFWSA-N (1r)-n-[[4-chloro-3-(1,2,4-triazol-1-yl)phenyl]methyl]-1-phenylethanamine Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(C=1)=CC=C(Cl)C=1N1C=NC=N1 GPFBWTUFZHDMRQ-CYBMUJFWSA-N 0.000 description 4
- LDEVTMZCQXFYDE-IKJXHCRLSA-N (1r)-n-[[4-chloro-3-(1-methylsulfonylpyrrolidin-3-yl)oxyphenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OC1CCN(S(C)(=O)=O)C1 LDEVTMZCQXFYDE-IKJXHCRLSA-N 0.000 description 4
- PMLLPQIGACARGX-PYUWXLGESA-N (1r)-n-[[4-chloro-3-[(1-methylpiperidin-3-yl)methoxy]phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1CCCN(C)C1 PMLLPQIGACARGX-PYUWXLGESA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- OWANQSWWFKPCLU-ZGTCLIOFSA-N 1-[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]propan-2-ol Chemical compound C1=C(Cl)C(OCC(O)C)=CC(CN[C@H](C)C=2C=C(Cl)C=CC=2)=C1 OWANQSWWFKPCLU-ZGTCLIOFSA-N 0.000 description 4
- CVQVKRSIFKXMON-LLVKDONJSA-N 2-[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]acetic acid Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC1=CC=C(Cl)C(OCC(O)=O)=C1 CVQVKRSIFKXMON-LLVKDONJSA-N 0.000 description 4
- WGQRBDCEEUUYKE-GFCCVEGCSA-N 2-[[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]methyl]-1,3-oxazole-4-carboxylic acid Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1=NC(C(O)=O)=CO1 WGQRBDCEEUUYKE-GFCCVEGCSA-N 0.000 description 4
- JBVIVVDESPFSIF-SNVBAGLBSA-N 2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC1=CC=C(Cl)C(S(N)(=O)=O)=C1 JBVIVVDESPFSIF-SNVBAGLBSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 229960005084 calcitriol Drugs 0.000 description 4
- 235000020964 calcitriol Nutrition 0.000 description 4
- 239000011612 calcitriol Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 150000002466 imines Chemical class 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- SAKDCESXMHKYSV-LLVKDONJSA-N (1r)-n-[(3-bromo-4-chlorophenyl)methyl]-1-phenylethanamine Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=C(Cl)C(Br)=C1 SAKDCESXMHKYSV-LLVKDONJSA-N 0.000 description 3
- UCOKVHKQZZOUCM-QGZVFWFLSA-N (1r)-n-[[3,4-dimethoxy-5-(4-methoxyphenyl)phenyl]methyl]-1-phenylethanamine Chemical compound C1=CC(OC)=CC=C1C1=CC(CN[C@H](C)C=2C=CC=CC=2)=CC(OC)=C1OC UCOKVHKQZZOUCM-QGZVFWFLSA-N 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- VQKDPTVTSDBUGA-GFCCVEGCSA-N 2-chloro-n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]acetamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=C(Cl)C(NC(=O)CCl)=C1 VQKDPTVTSDBUGA-GFCCVEGCSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- NLEPZGNUPNMRGF-UHFFFAOYSA-N 3-bromo-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Br)=C1 NLEPZGNUPNMRGF-UHFFFAOYSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002637 fluid replacement therapy Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000008991 intestinal motility Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- QPGNXTXBYRZYDW-GFCCVEGCSA-N methyl 2-[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]acetate Chemical compound C1=C(Cl)C(OCC(=O)OC)=CC(CN[C@H](C)C=2C=C(Cl)C=CC=2)=C1 QPGNXTXBYRZYDW-GFCCVEGCSA-N 0.000 description 3
- IOFNDNWNRIVABD-CYBMUJFWSA-N methyl 2-[[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]methyl]-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(COC=2C(=CC=C(CN[C@H](C)C=3C=C(Cl)C=CC=3)C=2)Cl)=N1 IOFNDNWNRIVABD-CYBMUJFWSA-N 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- PLLQAYXYPHFLEG-OAHLLOKOSA-N (1r)-1-(3-chlorophenyl)-n-[[4-chloro-3-(pyridin-2-ylmethoxy)phenyl]methyl]ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1=CC=CC=N1 PLLQAYXYPHFLEG-OAHLLOKOSA-N 0.000 description 2
- VKXGSUUWTQPWTQ-LJQANCHMSA-N (1r)-1-(4-methoxyphenyl)-n-[[3-(2-phenoxyethoxy)phenyl]methyl]ethanamine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NCC1=CC=CC(OCCOC=2C=CC=CC=2)=C1 VKXGSUUWTQPWTQ-LJQANCHMSA-N 0.000 description 2
- BYWQEZSARHEXQS-GFCCVEGCSA-N (1r)-n-[(3-bromo-4,5-dimethoxyphenyl)methyl]-1-phenylethanamine Chemical compound BrC1=C(OC)C(OC)=CC(CN[C@H](C)C=2C=CC=CC=2)=C1 BYWQEZSARHEXQS-GFCCVEGCSA-N 0.000 description 2
- BHYJDSBEXCNYHG-ITUIMRKVSA-N (1r)-n-[(3-cyclohex-2-en-1-yloxy-4-methoxyphenyl)methyl]-1-(4-methylphenyl)ethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)OC2C=CCCC2)OC)=CC=C(C)C=C1 BHYJDSBEXCNYHG-ITUIMRKVSA-N 0.000 description 2
- KDUIEABOADXJHU-LCQOSCCDSA-N (1r)-n-[(3-cyclohex-2-en-1-yloxy-4-methoxyphenyl)methyl]-1-naphthalen-1-ylethanamine Chemical compound COC1=CC=C(CN[C@H](C)C=2C3=CC=CC=C3C=CC=2)C=C1OC1CCCC=C1 KDUIEABOADXJHU-LCQOSCCDSA-N 0.000 description 2
- QEXAFIMEFADLJZ-DIAVIDTQSA-N (1r)-n-[(3-cyclohex-2-en-1-yloxy-4-methoxyphenyl)methyl]-1-phenylethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)OC2C=CCCC2)OC)=CC=CC=C1 QEXAFIMEFADLJZ-DIAVIDTQSA-N 0.000 description 2
- BDOVFVPIKYRXEF-MRXNPFEDSA-N (1r)-n-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1-(4-methoxyphenyl)ethanamine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NCC1=CC=C(OC)C(OC2CCCC2)=C1 BDOVFVPIKYRXEF-MRXNPFEDSA-N 0.000 description 2
- NJULOXUTWIQXCC-QGZVFWFLSA-N (1r)-n-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1-(4-methylphenyl)ethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)OC2CCCC2)OC)=CC=C(C)C=C1 NJULOXUTWIQXCC-QGZVFWFLSA-N 0.000 description 2
- ZQAOWNANNLPCQQ-GOSISDBHSA-N (1r)-n-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1-naphthalen-1-ylethanamine Chemical compound COC1=CC=C(CN[C@H](C)C=2C3=CC=CC=C3C=CC=2)C=C1OC1CCCC1 ZQAOWNANNLPCQQ-GOSISDBHSA-N 0.000 description 2
- RYEGZBVFQLQUTJ-MRXNPFEDSA-N (1r)-n-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1-phenylethanamine Chemical compound C1([C@@H](C)NCC2=CC=C(C(=C2)OC2CCCC2)OC)=CC=CC=C1 RYEGZBVFQLQUTJ-MRXNPFEDSA-N 0.000 description 2
- GCHQWWGDQNVAOQ-LLVKDONJSA-N (1r)-n-[(4-chloro-3-iodophenyl)methyl]-1-phenylethanamine Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=C(Cl)C(I)=C1 GCHQWWGDQNVAOQ-LLVKDONJSA-N 0.000 description 2
- VWLUFFWLJSJQHO-NFJWQWPMSA-N (1r)-n-[1-(3-bromo-4-chlorophenyl)ethyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(C)C1=CC=C(Cl)C(Br)=C1 VWLUFFWLJSJQHO-NFJWQWPMSA-N 0.000 description 2
- RIQPSXOEPQYESS-CQSZACIVSA-N (1r)-n-[[3-[(5-tert-butyl-1,2,4-oxadiazol-3-yl)methoxy]-4-chlorophenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1=NOC(C(C)(C)C)=N1 RIQPSXOEPQYESS-CQSZACIVSA-N 0.000 description 2
- GKMKEQUPEONWEZ-HSZRJFAPSA-N (1r)-n-[[3-[2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]ethoxy]phenyl]methyl]-1-(4-methoxyphenyl)ethanamine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NCC1=CC=CC(OCCN2CCN(CC=3C=C4OCOC4=CC=3)CC2)=C1 GKMKEQUPEONWEZ-HSZRJFAPSA-N 0.000 description 2
- DGTXTNUFROWJRW-OAHLLOKOSA-N (1r)-n-[[3-[tert-butyl(dimethyl)silyl]oxy-4-chlorophenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC1=CC=C(Cl)C(O[Si](C)(C)C(C)(C)C)=C1 DGTXTNUFROWJRW-OAHLLOKOSA-N 0.000 description 2
- HXAXAGNCTRJLOB-GFCCVEGCSA-N (1r)-n-[[4-chloro-3-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC=1N=CON=1 HXAXAGNCTRJLOB-GFCCVEGCSA-N 0.000 description 2
- AXECMRKIJVEOQN-MRXNPFEDSA-N (1r)-n-[[4-chloro-3-(2-morpholin-4-ylethoxy)phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCCN1CCOCC1 AXECMRKIJVEOQN-MRXNPFEDSA-N 0.000 description 2
- TVFDTUVLYXIITB-CQSZACIVSA-N (1r)-n-[[4-chloro-3-(6-methylpyridazin-3-yl)oxyphenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OC1=CC=C(C)N=N1 TVFDTUVLYXIITB-CQSZACIVSA-N 0.000 description 2
- UHUOCEABTDOJKN-CQSZACIVSA-N (1r)-n-[[4-chloro-3-[(1-methylimidazol-2-yl)methoxy]phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1=NC=CN1C UHUOCEABTDOJKN-CQSZACIVSA-N 0.000 description 2
- UVXQBJQVHUOENA-CYBMUJFWSA-N (1r)-n-[[4-chloro-3-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC=1C(C)=NOC=1C UVXQBJQVHUOENA-CYBMUJFWSA-N 0.000 description 2
- ZRNSVYRDKYOWCI-CQSZACIVSA-N (1r)-n-[[4-chloro-3-[(5-methyl-1,2-oxazol-3-yl)methoxy]phenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC=1C=C(C)ON=1 ZRNSVYRDKYOWCI-CQSZACIVSA-N 0.000 description 2
- NNFOXHQJUAOYEQ-HSZRJFAPSA-N (1r)-n-[[4-methoxy-3-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethoxy]phenyl]methyl]-1-naphthalen-1-ylethanamine Chemical compound COC1=CC=C(CN[C@H](C)C=2C3=CC=CC=C3C=CC=2)C=C1OCCN(CC1)CCN1C1=NC=CC=N1 NNFOXHQJUAOYEQ-HSZRJFAPSA-N 0.000 description 2
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
- GZSLTRDZOOSGGJ-KRWDZBQOSA-N (1s)-1-(3-methoxyphenyl)-n-[[3-(pyridin-2-ylmethoxy)phenyl]methyl]ethanamine Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCC=3N=CC=CC=3)C=CC=2)=C1 GZSLTRDZOOSGGJ-KRWDZBQOSA-N 0.000 description 2
- VLLHUZZJOZCYSG-QHCPKHFHSA-N (1s)-1-(3-methoxyphenyl)-n-[[3-[2-(4-phenylpiperazin-1-yl)ethoxy]phenyl]methyl]ethanamine Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C=3C=CC=CC=3)C=CC=2)=C1 VLLHUZZJOZCYSG-QHCPKHFHSA-N 0.000 description 2
- IFLCQLQTKHSZJD-NRFANRHFSA-N (1s)-1-(3-methoxyphenyl)-n-[[3-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethoxy]phenyl]methyl]ethanamine Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C=3N=CC=CN=3)C=CC=2)=C1 IFLCQLQTKHSZJD-NRFANRHFSA-N 0.000 description 2
- HUHDONFXBSPXSC-INIZCTEOSA-N (1s)-n-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OC3CCCC3)C(OC)=CC=2)=C1 HUHDONFXBSPXSC-INIZCTEOSA-N 0.000 description 2
- JOJIXPCAXJAIDS-SFHVURJKSA-N (1s)-n-[(3-morpholin-4-ylsulfonylphenyl)methyl]-1-naphthalen-1-ylethanamine Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1S(=O)(=O)N1CCOCC1 JOJIXPCAXJAIDS-SFHVURJKSA-N 0.000 description 2
- FNSGOKYUEILUDV-INIZCTEOSA-N (1s)-n-[(3-morpholin-4-ylsulfonylphenyl)methyl]-1-phenylethanamine Chemical compound N([C@@H](C)C=1C=CC=CC=1)CC(C=1)=CC=CC=1S(=O)(=O)N1CCOCC1 FNSGOKYUEILUDV-INIZCTEOSA-N 0.000 description 2
- RJYBHNNKQQFTPX-IBGZPJMESA-N (1s)-n-[[3-(2-phenoxyethoxy)phenyl]methyl]-1-phenylethanamine Chemical compound N([C@@H](C)C=1C=CC=CC=1)CC(C=1)=CC=CC=1OCCOC1=CC=CC=C1 RJYBHNNKQQFTPX-IBGZPJMESA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- WLNOSWNYESTEKE-UHFFFAOYSA-N 1-(3-bromo-4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(Br)=C1 WLNOSWNYESTEKE-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- KEOVDFFXSVRUSL-OAQYLSRUSA-N 1-[4-[2-[2-methoxy-5-[[[(1r)-1-naphthalen-1-ylethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=C(CN[C@H](C)C=2C3=CC=CC=C3C=CC=2)C=C1OCCN1CCN(C(C)=O)CC1 KEOVDFFXSVRUSL-OAQYLSRUSA-N 0.000 description 2
- ROVBNKZCXCGSGA-IBGZPJMESA-N 1-[4-[2-[2-methoxy-5-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C(C)=O)C(OC)=CC=2)=C1 ROVBNKZCXCGSGA-IBGZPJMESA-N 0.000 description 2
- WWNKUFNATJJVTC-IBGZPJMESA-N 1-[4-[2-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C(C)=O)C=CC=2)=C1 WWNKUFNATJJVTC-IBGZPJMESA-N 0.000 description 2
- WZZZFXCEJGXNPS-NRFANRHFSA-N 1-[4-[2-[3-[[[(1s)-1-naphthalen-1-ylethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1OCCN1CCN(C(C)=O)CC1 WZZZFXCEJGXNPS-NRFANRHFSA-N 0.000 description 2
- GNRQJAGNUZLSQP-FQEVSTJZSA-N 1-[4-[3-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]propyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCCN3CCN(CC3)C(C)=O)C=CC=2)=C1 GNRQJAGNUZLSQP-FQEVSTJZSA-N 0.000 description 2
- TUKLVIDJMMGTGN-QFIPXVFZSA-N 1-[4-[3-[3-[[[(1s)-1-naphthalen-1-ylethyl]amino]methyl]phenoxy]propyl]piperazin-1-yl]ethanone Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1OCCCN1CCN(C(C)=O)CC1 TUKLVIDJMMGTGN-QFIPXVFZSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- RYPKRALMXUUNKS-UHFFFAOYSA-N 2-Hexene Natural products CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 2
- WRKMVNFJIIVUHG-NRFANRHFSA-N 2-[2-methoxy-5-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl 4-(furan-2-carbonyl)piperazine-1-carboxylate Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCOC(=O)N3CCN(CC3)C(=O)C=3OC=CC=3)C(OC)=CC=2)=C1 WRKMVNFJIIVUHG-NRFANRHFSA-N 0.000 description 2
- MRNQVCCDFSFDOE-NRFANRHFSA-N 2-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl 4-(furan-2-carbonyl)piperazine-1-carboxylate Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCOC(=O)N3CCN(CC3)C(=O)C=3OC=CC=3)C=CC=2)=C1 MRNQVCCDFSFDOE-NRFANRHFSA-N 0.000 description 2
- PKYRYLYOTXILMN-IBGZPJMESA-N 2-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl 4-acetylpiperazine-1-carboxylate Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCOC(=O)N3CCN(CC3)C(C)=O)C=CC=2)=C1 PKYRYLYOTXILMN-IBGZPJMESA-N 0.000 description 2
- YFLAKJBAWRBKJC-NRFANRHFSA-N 2-[3-[[[(1s)-1-naphthalen-1-ylethyl]amino]methyl]phenoxy]ethyl 4-acetylpiperazine-1-carboxylate Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1OCCOC(=O)N1CCN(C(C)=O)CC1 YFLAKJBAWRBKJC-NRFANRHFSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- FFOIFAAVWJZLFE-UHFFFAOYSA-N 3-(chloromethyl)-1-methylpiperidine Chemical compound CN1CCCC(CCl)C1 FFOIFAAVWJZLFE-UHFFFAOYSA-N 0.000 description 2
- KLIDNCHOWGDFKQ-UHFFFAOYSA-N 3-amino-4-chlorobenzaldehyde Chemical compound NC1=CC(C=O)=CC=C1Cl KLIDNCHOWGDFKQ-UHFFFAOYSA-N 0.000 description 2
- KGAGEPOQWUSKCF-SECBINFHSA-N 3-bromo-4-chloro-n-[(1r)-1-(3-chlorophenyl)ethyl]benzamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(=O)C1=CC=C(Cl)C(Br)=C1 KGAGEPOQWUSKCF-SECBINFHSA-N 0.000 description 2
- FXVFKTNTUFYIQQ-UHFFFAOYSA-N 3-bromo-4-chloro-n-methoxy-n-methylbenzamide Chemical compound CON(C)C(=O)C1=CC=C(Cl)C(Br)=C1 FXVFKTNTUFYIQQ-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- HETBKLHJEWXWBM-UHFFFAOYSA-N 4-chloro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1Cl HETBKLHJEWXWBM-UHFFFAOYSA-N 0.000 description 2
- JGZVIZXYJBHFAH-CQSZACIVSA-N 4-chloro-n-[(1r)-1-(3-chlorophenyl)ethyl]-3-phenylsulfanylbenzamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(=O)C(C=1)=CC=C(Cl)C=1SC1=CC=CC=C1 JGZVIZXYJBHFAH-CQSZACIVSA-N 0.000 description 2
- ZVTWZSXLLMNMQC-UHFFFAOYSA-N 4-phenylmethoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 ZVTWZSXLLMNMQC-UHFFFAOYSA-N 0.000 description 2
- MXXLTNPIQOZBGI-ZGTOLYCTSA-N 5-[[2-chloro-5-[[[(1r)-1-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]methyl]-1,3-oxazolidin-2-one Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1OCC1CNC(=O)O1 MXXLTNPIQOZBGI-ZGTOLYCTSA-N 0.000 description 2
- XMVNMWDLOGSUSM-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carbonyl chloride Chemical compound CC1=CC(C(Cl)=O)=NO1 XMVNMWDLOGSUSM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000011213 Transient receptor potential channel, canonical 6 Human genes 0.000 description 2
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DODZSURBBAXONE-UHFFFAOYSA-N [5-(bromomethyl)-2-chlorophenoxy]-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(CBr)=CC=C1Cl DODZSURBBAXONE-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- XUAOJRZLUCOHIG-NRFANRHFSA-N furan-2-yl-[4-[2-[2-methoxy-5-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]methanone Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C(=O)C=3OC=CC=3)C(OC)=CC=2)=C1 XUAOJRZLUCOHIG-NRFANRHFSA-N 0.000 description 2
- ATOQZELFYBPCMZ-NRFANRHFSA-N furan-2-yl-[4-[2-[3-[[[(1s)-1-(3-methoxyphenyl)ethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]methanone Chemical compound COC1=CC=CC([C@H](C)NCC=2C=C(OCCN3CCN(CC3)C(=O)C=3OC=CC=3)C=CC=2)=C1 ATOQZELFYBPCMZ-NRFANRHFSA-N 0.000 description 2
- YUCLSVRJLNSNEF-QHCPKHFHSA-N furan-2-yl-[4-[2-[3-[[[(1s)-1-naphthalen-1-ylethyl]amino]methyl]phenoxy]ethyl]piperazin-1-yl]methanone Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)CC(C=1)=CC=CC=1OCCN(CC1)CCN1C(=O)C1=CC=CO1 YUCLSVRJLNSNEF-QHCPKHFHSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 210000001707 glomerular endothelial cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- IKJQMWUHTMLUBX-UHFFFAOYSA-N methyl 1-(2-amino-4-formylphenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC=C(C=O)C=C1N IKJQMWUHTMLUBX-UHFFFAOYSA-N 0.000 description 2
- WCOMEZPMSNLYBN-UHFFFAOYSA-N methyl 1-(2-chloro-5-formylphenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(C=O)=CC=C1Cl WCOMEZPMSNLYBN-UHFFFAOYSA-N 0.000 description 2
- GAPBUJMDWJXRPW-UHFFFAOYSA-N methyl 1-(4-formyl-2-nitrophenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC=C(C=O)C=C1[N+]([O-])=O GAPBUJMDWJXRPW-UHFFFAOYSA-N 0.000 description 2
- YSECMLMWVJWEOM-UHFFFAOYSA-N methyl 1-(5-formyl-2-nitrophenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(C=O)=CC=C1[N+]([O-])=O YSECMLMWVJWEOM-UHFFFAOYSA-N 0.000 description 2
- NEIRKPOTGUNMJH-UHFFFAOYSA-N methyl 1-[2-amino-5-(hydroxymethyl)phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(CO)=CC=C1N NEIRKPOTGUNMJH-UHFFFAOYSA-N 0.000 description 2
- CTNDNVXMUXHQOS-UHFFFAOYSA-N methyl 1-[2-chloro-5-(hydroxymethyl)phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(CO)=CC=C1Cl CTNDNVXMUXHQOS-UHFFFAOYSA-N 0.000 description 2
- XKINLGZEIVOYBV-UHFFFAOYSA-N methyl 4-methoxy-3-morpholin-4-ylsulfonylbenzoate Chemical compound COC(=O)C1=CC=C(OC)C(S(=O)(=O)N2CCOCC2)=C1 XKINLGZEIVOYBV-UHFFFAOYSA-N 0.000 description 2
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MNYXRAPBKSZDDF-UHFFFAOYSA-N n-(2-chloro-5-formylphenyl)-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NC=2C(=CC=C(C=O)C=2)Cl)=N1 MNYXRAPBKSZDDF-UHFFFAOYSA-N 0.000 description 2
- JYXJDSONOREHHD-CQSZACIVSA-N n-[(1r)-1-(3-chlorophenyl)ethyl]-4-methoxy-3-morpholin-4-ylsulfonylbenzamide Chemical compound COC1=CC=C(C(=O)N[C@H](C)C=2C=C(Cl)C=CC=2)C=C1S(=O)(=O)N1CCOCC1 JYXJDSONOREHHD-CQSZACIVSA-N 0.000 description 2
- INVDZQKPSHNRNU-CQSZACIVSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]-2,2-dimethylpropanamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=C(Cl)C(NC(=O)C(C)(C)C)=C1 INVDZQKPSHNRNU-CQSZACIVSA-N 0.000 description 2
- QFZBKINBEQMIKK-GFCCVEGCSA-N n-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]acetamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=C(Cl)C(NC(C)=O)=C1 QFZBKINBEQMIKK-GFCCVEGCSA-N 0.000 description 2
- RCHKEJKUUXXBSM-UHFFFAOYSA-N n-benzyl-2-(3-formylindol-1-yl)acetamide Chemical compound C12=CC=CC=C2C(C=O)=CN1CC(=O)NCC1=CC=CC=C1 RCHKEJKUUXXBSM-UHFFFAOYSA-N 0.000 description 2
- 238000012148 non-surgical treatment Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- QMMOXUPEWRXHJS-UHFFFAOYSA-N pentene-2 Natural products CCC=CC QMMOXUPEWRXHJS-UHFFFAOYSA-N 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LBKJNHPKYFYCLL-UHFFFAOYSA-N potassium;trimethyl(oxido)silane Chemical compound [K+].C[Si](C)(C)[O-] LBKJNHPKYFYCLL-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WKBFVGPNLRCTCB-UHFFFAOYSA-N tert-butyl-(2-chloro-5-methylphenoxy)-dimethylsilane Chemical compound CC1=CC=C(Cl)C(O[Si](C)(C)C(C)(C)C)=C1 WKBFVGPNLRCTCB-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- LUZOFMGZMUZSSK-LRDDRELGSA-N (-)-indolactam V Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-LRDDRELGSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- ASNVMKIDRJZXQZ-ZCFIWIBFSA-N (1r)-1-(3-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-ZCFIWIBFSA-N 0.000 description 1
- ZVNMTUNTMZGHJN-LLVKDONJSA-N (1r)-n-[(3-bromo-4-methoxyphenyl)methyl]-1-(3-fluorophenyl)ethanamine Chemical compound C1=C(Br)C(OC)=CC=C1CN[C@H](C)C1=CC=CC(F)=C1 ZVNMTUNTMZGHJN-LLVKDONJSA-N 0.000 description 1
- NTHZQKKKGGDTJZ-GJNAARLKSA-N (1r)-n-[[3-(benzenesulfinyl)-4-chlorophenyl]methyl]-1-(3-chlorophenyl)ethanamine Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)CC(C=1)=CC=C(Cl)C=1S(=O)C1=CC=CC=C1 NTHZQKKKGGDTJZ-GJNAARLKSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- YCTDZYMMFQCTEO-FNORWQNLSA-N (E)-3-octene Chemical compound CCCC\C=C\CC YCTDZYMMFQCTEO-FNORWQNLSA-N 0.000 description 1
- JINQHBRSXWQJAZ-UHFFFAOYSA-N 1,2-diphenylpropan-2-amine Chemical compound C=1C=CC=CC=1C(N)(C)CC1=CC=CC=C1 JINQHBRSXWQJAZ-UHFFFAOYSA-N 0.000 description 1
- ASNVMKIDRJZXQZ-UHFFFAOYSA-N 1-(3-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-UHFFFAOYSA-N 0.000 description 1
- PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NOMWMFNPNMHIGI-UHFFFAOYSA-N 1-methylsulfonylpyrrolidin-3-ol Chemical compound CS(=O)(=O)N1CCC(O)C1 NOMWMFNPNMHIGI-UHFFFAOYSA-N 0.000 description 1
- OMNCAMLXMUWIRR-UHFFFAOYSA-N 1-phenylpentane-2,3-diamine Chemical class CCC(N)C(N)CC1=CC=CC=C1 OMNCAMLXMUWIRR-UHFFFAOYSA-N 0.000 description 1
- PPHIIIRFJKDTLG-UHFFFAOYSA-N 1-pyridin-2-ylethanol Chemical compound CC(O)C1=CC=CC=N1 PPHIIIRFJKDTLG-UHFFFAOYSA-N 0.000 description 1
- OLFLFCAHZFGBNS-UHFFFAOYSA-N 1664-31-9 Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NCCN1CCCCC1 OLFLFCAHZFGBNS-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- OTTZHAVKAVGASB-HYXAFXHYSA-N 2-Heptene Chemical compound CCCC\C=C/C OTTZHAVKAVGASB-HYXAFXHYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WKIVBBWLRIFGHF-UHFFFAOYSA-N 2-chloro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1Cl WKIVBBWLRIFGHF-UHFFFAOYSA-N 0.000 description 1
- NLAPZJWTOIYFAW-NFJWQWPMSA-N 2-chloro-5-[1-[[(1r)-1-(3-chlorophenyl)ethyl]amino]ethyl]aniline Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(C)C1=CC=C(Cl)C(N)=C1 NLAPZJWTOIYFAW-NFJWQWPMSA-N 0.000 description 1
- SMFHPCZZAAMJJO-UHFFFAOYSA-N 2-chloro-5-methylphenol Chemical compound CC1=CC=C(Cl)C(O)=C1 SMFHPCZZAAMJJO-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- OTTZHAVKAVGASB-UHFFFAOYSA-N 2-heptene Natural products CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 1
- QCFAKTACICNQGT-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxymethoxymethoxy]propane Chemical compound CC(C)(C)OCOCOC(C)(C)C QCFAKTACICNQGT-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ICVODPFGWCUVJC-UHFFFAOYSA-N 3-bromo-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(Br)=C1OC ICVODPFGWCUVJC-UHFFFAOYSA-N 0.000 description 1
- LBIWUCOXZXNQIS-SNVBAGLBSA-N 3-bromo-4-chloro-n-[(1r)-1-phenylethyl]benzamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)C1=CC=C(Cl)C(Br)=C1 LBIWUCOXZXNQIS-SNVBAGLBSA-N 0.000 description 1
- QMPNFQLVIGPNEI-UHFFFAOYSA-N 3-bromo-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1Br QMPNFQLVIGPNEI-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- BWUIGISQVCIQBT-UHFFFAOYSA-N 3-fluoro-4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1F BWUIGISQVCIQBT-UHFFFAOYSA-N 0.000 description 1
- ZQDPJFUHLCOCRG-UHFFFAOYSA-N 3-hexene Chemical compound CCC=CCC ZQDPJFUHLCOCRG-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical compound CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- FHQAWINGVCDTTG-UHFFFAOYSA-N 4-chloro-3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC(C(O)=O)=CC=C1Cl FHQAWINGVCDTTG-UHFFFAOYSA-N 0.000 description 1
- IOMQYTXSIUCMQC-SECBINFHSA-N 4-chloro-n-[(1r)-1-(3-chlorophenyl)ethyl]-3-sulfamoylbenzamide Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 IOMQYTXSIUCMQC-SECBINFHSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- CIMGPVLMSMHBMD-UHFFFAOYSA-N 4-methoxy-3-morpholin-4-ylsulfonylbenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1S(=O)(=O)N1CCOCC1 CIMGPVLMSMHBMD-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- JIUFYGIESXPUPL-UHFFFAOYSA-N 5-methylhex-1-ene Chemical compound CC(C)CCC=C JIUFYGIESXPUPL-UHFFFAOYSA-N 0.000 description 1
- DFVOXRAAHOJJBN-UHFFFAOYSA-N 6-methylhept-1-ene Chemical compound CC(C)CCCC=C DFVOXRAAHOJJBN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000037411 Aortic calcification Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910014265 BrCl Inorganic materials 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- VYLJAYXZTOTZRR-BTPDVQIOSA-N CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C Chemical compound CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C VYLJAYXZTOTZRR-BTPDVQIOSA-N 0.000 description 1
- IOMQYTXSIUCMQC-UHFFFAOYSA-N CC(c1cc(Cl)ccc1)NC(c(cc1S(N)(=O)=O)ccc1Cl)=O Chemical compound CC(c1cc(Cl)ccc1)NC(c(cc1S(N)(=O)=O)ccc1Cl)=O IOMQYTXSIUCMQC-UHFFFAOYSA-N 0.000 description 1
- WGKDGYKCRPDIKK-UHFFFAOYSA-N CC1N(CCCC1)C1=C(C=C(C=C1)C=O)NC(=O)C1=NOC(=C1)C Chemical compound CC1N(CCCC1)C1=C(C=C(C=C1)C=O)NC(=O)C1=NOC(=C1)C WGKDGYKCRPDIKK-UHFFFAOYSA-N 0.000 description 1
- 102100027209 CD2-associated protein Human genes 0.000 description 1
- 0 C[C@](c1cc(Cl)ccc1)NCc(cc1S(N)(=*)=O)ccc1Cl Chemical compound C[C@](c1cc(Cl)ccc1)NCc(cc1S(N)(=*)=O)ccc1Cl 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 108091006068 Gq proteins Proteins 0.000 description 1
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000914499 Homo sapiens CD2-associated protein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- LUZOFMGZMUZSSK-UHFFFAOYSA-N Indolactam-V Natural products C1C(CO)NC(=O)C(C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-UHFFFAOYSA-N 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- KTVBMMNJDGGFAL-UHFFFAOYSA-N NCS(c1cc(C(O)=O)ccc1Cl)(=O)=O Chemical compound NCS(c1cc(C(O)=O)ccc1Cl)(=O)=O KTVBMMNJDGGFAL-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100023195 Nephrin Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010033964 Parathyroid tumour benign Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229940124034 Phospholipase C inhibitor Drugs 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004045 azirinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- GSYUXYXARXLYDO-UHFFFAOYSA-N butanedioic acid;2-hydroxybenzoic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)C1=CC=CC=C1O GSYUXYXARXLYDO-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000004600 colonic motility Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- WZHKDGJSXCTSCK-UHFFFAOYSA-N hept-3-ene Chemical compound CCCC=CCC WZHKDGJSXCTSCK-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- VYLJAYXZTOTZRR-UHFFFAOYSA-N hopane-6alpha,7beta,22-triol Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)C(O)C3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C VYLJAYXZTOTZRR-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940095970 imodium Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229950006319 maxacalcitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- FFOXOMJGURMBHD-UHFFFAOYSA-N methyl 1-(2-amino-5-formylphenyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(C=O)=CC=C1N FFOXOMJGURMBHD-UHFFFAOYSA-N 0.000 description 1
- BYFYMLAAKDUODY-MRXNPFEDSA-N methyl 1-[2-chloro-5-[[[(1r)-1-phenylethyl]amino]methyl]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC(CN[C@H](C)C=2C=CC=CC=2)=CC=C1Cl BYFYMLAAKDUODY-MRXNPFEDSA-N 0.000 description 1
- UPMAWRZZCPHHLQ-UHFFFAOYSA-N methyl 1-[4-formyl-2-[(5-methyl-1,2-oxazole-3-carbonyl)amino]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C1=CC=C(C=O)C=C1NC(=O)C1=NOC(C)=C1 UPMAWRZZCPHHLQ-UHFFFAOYSA-N 0.000 description 1
- CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 108010027531 nephrin Proteins 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229940064764 noroxin Drugs 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- IRUCBBFNLDIMIK-UHFFFAOYSA-N oct-4-ene Chemical compound CCCC=CCCC IRUCBBFNLDIMIK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000011116 pancreatic cholera Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 201000003686 parathyroid adenoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 208000014643 parathyroid gland adenoma Diseases 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229940101070 pepto-bismol Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003371 phospholipase C inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000006578 reductive coupling reaction Methods 0.000 description 1
- 229940020428 renagel Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- COZRIRIUJMAMIN-CQSZACIVSA-N tert-butyl n-[(3-bromo-4-methoxyphenyl)methyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]carbamate Chemical compound C1=C(Br)C(OC)=CC=C1CN(C(=O)OC(C)(C)C)[C@H](C)C1=CC=CC(F)=C1 COZRIRIUJMAMIN-CQSZACIVSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940063678 vibramycin Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
本願は、2006年10月26日に出願された米国仮特許出願第60/854,909号の優先権の利益を主張するものである。
本発明は、一般に医薬品の分野に関し、より具体的には、カルシウム受容体調節化合物及びそれを含む薬剤組成物に関する。
更に別の一態様においては、R5は、置換又は非置換ピペリジルであり得、置換基は、ハロゲン、−ORb、−NRaRd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、シアノ、ニトロ、−NRaS(=O)nRc又は−S(=O)nNRaRdから選択され得る。
(R)−N−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)アセトアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−フランカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1,3−ジメチル−1H−ピラゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−フェニルプロパンアミド、
2−クロロ−N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)アセトアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2,2−ジメチルプロパンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)ベンズアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−メチル−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−ピリジンカルボキサミド、
フェニルメチル(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)カルバマート、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2,5−ジメチル−1,3−オキサゾール−4−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−メチル−1,2,3−チアジアゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−メチル−1,3−チアゾル−4−イル)−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−N’−フェニル尿素、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1−(1,1−ジメチルエチル)−5−メチル−1H−ピラゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−3−イソオキサゾールカルボキサミド、
6−クロロ−N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−ピリジニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−(1−ナフタレニル)エチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
(R)−N−(4−クロロ−3−ニトロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(フェニルチオ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(フェニルスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)ベンゼンスルホンアミド、
(R)−N−(4−メトキシ−3−(モルホリノスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(モルホリノスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−2−(ピロリジン−1−イル)アセトアミド、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−6−(ジメチルアミノ)ニコチンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−モルホリニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−メチル−1−ピペラジニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−(ジメチルアミノ)エチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(メチルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(フェニルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((フェニルメチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−フェニルエチル)アミノ)−3−ピリジンカルボキサミド、
(R)−1−(2−(5−メチルイソオキサゾール−3−カルボキサミド)−4−((1−フェニルエチルアミノ)メチル)フェニル)ピペリジン−4−カルボキサミド、
(R)−1−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)ピペリジン−4−カルボキサミド、
(R)−2−クロロ−5−((1−フェニルエチルアミノ)メチル)−N−(ピリジン−2−イルメチル)ベンゼンアミン、
(1R)−N−(3−(1H−ベンゾ[d]イミダゾル−1−イル)−4−クロロベンジル)−1−フェニルエタンアミン、
(1R)−N−(4−クロロ−3−(1H−1,2,4−トリアゾル−1−イル)ベンジル)−1−フェニルエタンアミン、
((1R)−N−(4−クロロ−3−((1−メチルピペリジン−3−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−メチル2−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)アセタート、
(R)−N−(3−((1,2,4−オキサジアゾル−3−イル)メトキシ)−4−クロロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−((5−メチルイソオキサゾル−3−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−((1−メチル−1H−イミダゾル−2−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(3−((5−tert−ブチル−1,2,4−オキサジアゾル−3−イル)メトキシ)−4−クロロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−メチル2−((2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾール−4−カルボキシラート、
(R)−N−(4−クロロ−3−(6−メチルピリダジン−3−イルオキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(2−モルホリノエトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(ピリジン−2−イルメトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
5−((2−クロロ−5−(((R)−1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾリジン−2−オン、
(R)−N−(4−クロロ−3−((3,5−ジメチルイソオキサゾル−4−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
1−(2−クロロ−5−(((R)−1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)プロパン−2−オール、
(1R)−N−(4−クロロ−3−(1−(ピリジン−2−イル)エトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(1R)−N−(4−クロロ−3−(1−(メチルスルホニル)ピロリジン−3−イルオキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−2−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)酢酸、
(R)−2−((2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾール−4−カルボン酸、
N−(2−クロロ−5−(1−((R)−1−(3−クロロフェニル)エチルアミノ)エチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
(R)−N−(3−(4−メトキシフェニル)−4,5−ジメトキシベンジル)−1−フェニルエタンアミン、
(R)−N−(4−メトキシ−3−(ピロリジン−1−イル)ベンジル)−1−(3−フルオロフェニル)エタンアミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−[(S)−1−(3−メトキシ−フェニル)−エチル]−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−p−トリル−エチル)−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−ナフタレン−1−イル−エチル)−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−フェニル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−p−トリル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−ナフタレン−1−イル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−フェニル−エチル)−アミン、
[(R)−1−(4−メトキシ−フェニル)−エチル]−[3−(2−フェノキシ−エトキシ)−ベンジル]−アミン、
[3−(2−フェノキシ−エトキシ)−ベンジル]−((S)−1−フェニル−エチル)−アミン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−[3−(ピリジン−2−イルメトキシ)−ベンジル]−アミン、
((S)−1−ナフタレン−1−イル−エチル)−[3−(ピリジン−2−イルメトキシ)−ベンジル]−アミン、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−p−トリル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−フェニル−エチルアミノ)−メチル]−フェニル}−アミド、
チオフェン−2−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
チオフェン−2−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
1−{4−[2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−エタノン、
1−[4−(2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−エタノン、
4−アセチル−ピペラジン−1−カルボン酸2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
4−アセチル−ピペラジン−1−カルボン酸2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチルエステル、
1−{4−[3−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−プロピル]−ピペラジン−1−イル}−エタノン、
1−[4−(3−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−プロピル)−ピペラジン−1−イル]−エタノン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−{3−[2−(4−フェニル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
((S)−1−ナフタレン−1−イル−エチル)−{3−[2−(4−フェニル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
N−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−2−ピロリジン−1−イル−アセトアミド、
N−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−2−ピロリジン−1−イル−アセトアミド、
フラン−2−イル−[4−(2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−メタノン、
1−{4−[2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−エタノン、
1−[4−(2−{2−メトキシ−5−[((R)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−エタノン、
フラン−2−イル−{4−[2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−メタノン、
{4−メトキシ−3−[2−(4−ピリミジン−2−イル−ピペラジン−1−イル)−エトキシ]−ベンジル}−((R)−1−ナフタレン−1−イル−エチル)−アミン、
4−(フラン−2−カルボニル)−ピペラジン−1−カルボン酸2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
[(S)−1−(3−メトキシ−フェニル)−エチル]−{3−[2−(4−ピリミジン−2−イル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
4−(フラン−2−カルボニル)−ピペラジン−1−カルボン酸2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
{3−[2−(4−ベンゾ[1,3]ジオキソル−5−イルメチル−ピペラジン−1−イル)−エトキシ]−ベンジル}−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
フラン−2−イル−{4−[2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−メタノン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−[3−(モルホリン−4−スルホニル)−ベンジル]−アミン、
[3−(モルホリン−4−スルホニル)−ベンジル]−((S)−1−ナフタレン−1−イル−エチル)−アミン、
[3−(モルホリン−4−スルホニル)−ベンジル]−((S)−1−フェニル−エチル)−アミン、
((S)−1−ナフタレン−1−イル−エチル)−[3−(ピペリジン−1−スルホニル)−ベンジル]−アミン、
((S)−1−フェニル−エチル)−[3−(ピペリジン−1−スルホニル)−ベンジル]−アミン、及び
N−{2−メトキシ−5−[((R)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−N−メチル−ベンズアミド。
疾患を「治療すること」又は疾患の「治療」は、(1)疾患を防止すること、すなわち、疾患に、若しくは疾患を引き起こし得る条件に曝され得る、若しくは曝された対象において、又は罹患しやすいが、疾患の症候をまだ経験していない、若しくは示していない対象において、疾患の臨床症状を発生させないこと、(2)疾患を抑制すること、すなわち、疾患又はその臨床症状のいずれかの発生を抑止又は低減すること、又は(3)疾患を軽減すること、すなわち、疾患又はその臨床症状のいずれかを後退させることを含む。
本明細書では「カルシウム模倣化合物」又は「カルシウム擬態薬」という用語は、カルシウム感知受容体に結合し、内因性リガンドCa2+によってカルシウム感知受容体活性化のしきい値を低下させる高次構造上の変化を引き起こす化合物を指す。これらのカルシウム模倣化合物は、カルシウム受容体のアロステリックモジュレーターと考えることもできる。
R2はC1−8アルキル又はC1−4ハロアルキルであり、
R3はH、C1−4ハロアルキル又はC1−8アルキルであり、
R4はH、C1−4ハロアルキル又はC1−8アルキルであり、
R5は、独立に、各場合において、H、C1−8アルキル、C1−4ハロアルキル、ハロゲン、−OC1−6アルキル、−NRaRd、NRaC(=O)Rd、置換若しくは非置換ピロリジニル、置換若しくは非置換アゼチジニル、又は置換若しくは非置換ピペリジルであって、置換基は、ハロゲン、−ORb、−NRaRd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、シアノ、ニトロ、−NRaS(=O)nRc又は−S(=O)nNRaRdから選択することができ、
Lは、−O−、−OC1−6アルキル−、−C1−6アルキルO−、−N(Ra)(Rd)−、−NRaC(=O)−、−C(=O)−、−C(=O)NRdC1−6アルキル−、−C1−6アルキル−C(=O)NRd−、−NRdC(=O)NRd−、−NRdC(=O)NRdC1−6アルキル−、−NRaC(=O)Rc−、−NRaC(=O)ORc−、−OC1−6アルキル−C(=O)O−、−NRdC1−6アルキル−、−C1−6アルキルNRd−、−S−、−S(=O)n−、−NRaS(=O)n又は−S(=O)nN(Ra)−であり、
Cyは、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、R6、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
R6は、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
Raは、独立に、各場合において、H、C1−4ハロアルキル、C1−6アルキル、C1−6アルケニル、C1−6アルキルアリール又はアリールC1−6アルキルであり、
Rbは、独立に、各場合において、C1−8アルキル、C1−4ハロアルキル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、フェニル、ベンジル、ナフチル又は複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロから選択される0、1、2又は3個の置換基で置換され、
Rcは、独立に、各場合において、C1−6アルキル、C1−4ハロアルキル、フェニル又はベンジルであり、
Rdは、独立に、各場合において、H、C1−6アルキル、C1−6アルケニル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、C1−6アルキル、フェニル、ベンジル、ナフチル及び複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロ、Rb、−C(=O)Rc、−ORb、−NRaRb、−C(=O)ORc、−C(=O)NRaRb、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc及び−S(=O)mNRaRaから選択される0、1、2、3又は4個の置換基で置換され、
mは1又は2であり、
nは1又は2であり、
ただし、Lが−O−又は−OC1−6アルキル−である場合、Cyはフェニルではない。
(R)−N−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)アセトアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−フランカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1,3−ジメチル−1H−ピラゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−フェニルプロパンアミド,
2−クロロ−N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)アセトアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2,2−ジメチルプロパンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)ベンズアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−メチル−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−ピリジンカルボキサミド、
フェニルメチル(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)カルバマート、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2,5−ジメチル−1,3−オキサゾール−4−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−メチル−1,2,3−チアジアゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−メチル−1,3−チアゾル−4−イル)−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−N’−フェニル尿素、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1−(1,1−ジメチルエチル)−5−メチル−1H−ピラゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−3−イソオキサゾールカルボキサミド、
6−クロロ−N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−ピリジニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−(1−ナフタレニル)エチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
(R)−N−(4−クロロ−3−ニトロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(フェニルチオ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(フェニルスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)ベンゼンスルホンアミド、
(R)−N−(4−メトキシ−3−(モルホリノスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(モルホリノスルホニル)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−2−(ピロリジン−1−イル)アセトアミド、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−6−(ジメチルアミノ)ニコチンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−モルホリニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−メチル−1−ピペラジニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−(ジメチルアミノ)エチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(メチルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(フェニルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((フェニルメチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−フェニルエチル)アミノ)−3−ピリジンカルボキサミド、
(R)−1−(2−(5−メチルイソオキサゾール−3−カルボキサミド)−4−((1−フェニルエチルアミノ)メチル)フェニル)ピペリジン−4−カルボキサミド、
(R)−1−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)ピペリジン−4−カルボキサミド、
(R)−2−クロロ−5−((1−フェニルエチルアミノ)メチル)−N−(ピリジン−2−イルメチル)ベンゼンアミン、
(1R)−N−(3−(1H−ベンゾ[d]イミダゾル−1−イル)−4−クロロベンジル)−1−フェニルエタンアミン、
(1R)−N−(4−クロロ−3−(1H−1,2,4−トリアゾル−1−イル)ベンジル)−1−フェニルエタンアミン、
((1R)−N−(4−クロロ−3−((1−メチルピペリジン−3−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−メチル2−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)アセタート、
(R)−N−(3−((1,2,4−オキサジアゾル−3−イル)メトキシ)−4−クロロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−((5−メチルイソオキサゾル−3−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−((1−メチル−1H−イミダゾル−2−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(3−((5−tert−ブチル−1,2,4−オキサジアゾル−3−イル)メトキシ)−4−クロロベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−メチル2−((2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾール−4−カルボキシラート、
(R)−N−(4−クロロ−3−(6−メチルピリダジン−3−イルオキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(2−モルホリノエトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−N−(4−クロロ−3−(ピリジン−2−イルメトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
5−((2−クロロ−5−(((R)−1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾリジン−2−オン、
(R)−N−(4−クロロ−3−((3,5−ジメチルイソオキサゾル−4−イル)メトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
1−(2−クロロ−5−(((R)−1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)プロパン−2−オール、
(1R)−N−(4−クロロ−3−(1−(ピリジン−2−イル)エトキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(1R)−N−(4−クロロ−3−(1−(メチルスルホニル)ピロリジン−3−イルオキシ)ベンジル)−1−(3−クロロフェニル)エタンアミン、
(R)−2−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)酢酸、
(R)−2−((2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェノキシ)メチル)オキサゾール−4−カルボン酸、
N−(2−クロロ−5−(1−((R)−1−(3−クロロフェニル)エチルアミノ)エチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
(R)−N−(3−(4−メトキシフェニル)−4,5−ジメトキシベンジル)−1−フェニルエタンアミン、
(R)−N−(4−メトキシ−3−(ピロリジン−1−イル)ベンジル)−1−(3−フルオロフェニル)エタンアミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−[(S)−1−(3−メトキシ−フェニル)−エチル]−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−p−トリル−エチル)−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−ナフタレン−1−イル−エチル)−アミン、
(3−シクロペンチルオキシ−4−メトキシ−ベンジル)−((R)−1−フェニル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−p−トリル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−ナフタレン−1−イル−エチル)−アミン、
[3−(シクロヘキサ−2−エニルオキシ)−4−メトキシ−ベンジル]−((R)−1−フェニル−エチル)−アミン、
[(R)−1−(4−メトキシ−フェニル)−エチル]−[3−(2−フェノキシ−エトキシ)−ベンジル]−アミン、
[3−(2−フェノキシ−エトキシ)−ベンジル]−((S)−1−フェニル−エチル)−アミン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−[3−(ピリジン−2−イルメトキシ)−ベンジル]−アミン、
((S)−1−ナフタレン−1−イル−エチル)−[3−(ピリジン−2−イルメトキシ)−ベンジル]−アミン、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−p−トリル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−フェニル−エチルアミノ)−メチル]−フェニル}−アミド、
チオフェン−2−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
チオフェン−2−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
1−{4−[2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−エタノン、
1−[4−(2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−エタノン、
4−アセチル−ピペラジン−1−カルボン酸2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
4−アセチル−ピペラジン−1−カルボン酸2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチルエステル、
1−{4−[3−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−プロピル]−ピペラジン−1−イル}−エタノン、
1−[4−(3−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−プロピル)−ピペラジン−1−イル]−エタノン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−{3−[2−(4−フェニル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
((S)−1−ナフタレン−1−イル−エチル)−{3−[2−(4−フェニル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
N−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−2−ピロリジン−1−イル−アセトアミド、
N−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−2−ピロリジン−1−イル−アセトアミド、
フラン−2−イル−[4−(2−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−メタノン、
1−{4−[2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−エタノン、
1−[4−(2−{2−メトキシ−5−[((R)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェノキシ}−エチル)−ピペラジン−1−イル]−エタノン、
フラン−2−イル−{4−[2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−メタノン、
{4−メトキシ−3−[2−(4−ピリミジン−2−イル−ピペラジン−1−イル)−エトキシ]−ベンジル}−((R)−1−ナフタレン−1−イル−エチル)−アミン、
4−(フラン−2−カルボニル)−ピペラジン−1−カルボン酸2−(2−メトキシ−5−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
[(S)−1−(3−メトキシ−フェニル)−エチル]−{3−[2−(4−ピリミジン−2−イル−ピペラジン−1−イル)−エトキシ]−ベンジル}−アミン、
4−(フラン−2−カルボニル)−ピペラジン−1−カルボン酸2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチルエステル、
{3−[2−(4−ベンゾ[1,3]ジオキソル−5−イルメチル−ピペラジン−1−イル)−エトキシ]−ベンジル}−[(R)−1−(4−メトキシ−フェニル)−エチル]−アミン、
フラン−2−イル−{4−[2−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェノキシ)−エチル]−ピペラジン−1−イル}−メタノン、
[(S)−1−(3−メトキシ−フェニル)−エチル]−[3−(モルホリン−4−スルホニル)−ベンジル]−アミン、
[3−(モルホリン−4−スルホニル)−ベンジル]−((S)−1−ナフタレン−1−イル−エチル)−アミン、
[3−(モルホリン−4−スルホニル)−ベンジル]−((S)−1−フェニル−エチル)−アミン、
((S)−1−ナフタレン−1−イル−エチル)−[3−(ピペリジン−1−スルホニル)−ベンジル]−アミン、
((S)−1−フェニル−エチル)−[3−(ピペリジン−1−スルホニル)−ベンジル]−アミン、及び
N−{2−メトキシ−5−[((R)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−N−メチル−ベンズアミド。
下記方法A−Hは、本発明の化合物を調製する例示的な合成方法である。当業者は、その他の方法も有用であることを理解されたい。換言すれば、本発明の化合物は、当分野で周知の出発材料、試薬及び反応を用いた有機合成によって製造することができる。
本発明に有用である化合物は、無機酸又は有機酸から誘導される、薬学的に許容される塩の形で使用することができる。塩としては、酢酸塩、アジピン酸塩、アルギン酸塩、クエン酸塩、アスパラギン酸塩、安息香酸塩、ベンゼンスルホン酸塩、硫酸水素塩、酪酸塩、ショウノウ酸塩、カンファースルホン酸塩、ジグルコン酸塩、シクロペンタンプロピオン酸塩、ドデシル硫酸塩、エタンスルホン酸塩、グルコヘプタン酸塩、グリセロリン酸塩、1/2硫酸塩、ヘプタン酸塩、ヘキサン酸塩、フマル酸塩、塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、2−ヒドロキシエタンスルホン酸塩、乳酸塩、マレイン酸塩、マンデル酸塩、メタンスルホン酸塩、ニコチン酸塩、2−ナフタレンスルホン酸塩、シュウ酸塩、パモ酸塩(palmoate)、ペクチン酸塩、過硫酸塩、2−フェニルプロピオン酸塩、ピクリン酸塩、ピバリン酸塩、プロピオン酸塩、サリチル酸塩、コハク酸塩、硫酸塩、酒石酸塩、チオシアン酸塩、トシル酸塩、メシル酸塩及びウンデカン酸塩が挙げられるが、これらだけに限定されない。本発明の化合物がカルボキシ基などの酸性官能基を含むときには、適切な薬学的に許容されるカルボキシ基の塩は、当業者に周知であり、例えば、アルカリ、アルカリ土類、アンモニウム、第4級アンモニウム陽イオンなどが挙げられる。「薬理学的に許容される塩」の追加の例については、以下及びBerge et al.,J.Pharm.Sci.66:1, 1977を参照されたい。本発明のある実施形態においては、塩酸塩及びメタンスルホン酸塩を使用することができる。
したがって、カルシウム受容体に作用する本願の化合物及び組成物は、一態様においては、無機イオン受容体及び、特に、細胞外カルシウムに結合可能な膜カルシウム受容体などのカルシウム受容体の異常な生理学的挙動と関連した疾患又は障害の治療又は防止に使用することができる。したがって、本発明の化合物及び組成物は、PTH及び細胞外Ca2+の血清レベルの調節に特に有用である。本発明の化合物及び組成物は、特に、PTHとして知られる副甲状腺ホルモンにおける血清レベルの減少に関与するのに使用することができ、したがって、これらの生成物は、一態様においては、副甲状腺機能亢進症などの疾患の治療に有用であり得る。同様に、高カルシウム血症などのカルシウムホメオスタシスの異常も、これらの化合物を用いて治療することができる。さらに、本発明の化合物は、過形成及び副甲状腺腺腫を治療することもできる。別の一態様においては、本発明の化合物は、循環PTHレベルの変動に直接依存する骨吸収を本発明の化合物が減少できるようにする性質を有し得、これらの生成物は、特に、骨粗しょう症、骨減少症 パジェット病、骨折の再建などの疾患の治療に有用であり得る。本発明の化合物は、多発性関節炎及び骨関節炎の治療及び予防に使用することもできる。
この粗生成物をジオキサン中の4M HCl 3mLと一緒に20℃で24時間撹拌した。溶媒を除去した後、粗生成物をGilson HPLCによって精製して、所望の生成物(R)−N−(4−メトキシ−3−(ピロリジン−1−イル)ベンジル)−1−(3−フルオロフェニル)エタンアミン118を白色固体のTFA塩として得た。LCMS(M+1)329、C20H25FN2Oの計算値329;1H NMR(400MHz、メタノール−d4)δ ppm 1.62(d、J=6.8Hz、3H)2.10(bs、4H)3.55(bs、4H)3.85(d、J=13Hz、1H)3.89(s、3H)、4.06(d、J=13Hz、1H)4.39(q、J=6.8Hz、1H)7.12−7.23(m、4H)7.3(s、1H)、7.38−7.43(m、2H)。
カルシウム受容体に対する本発明の化合物の活性を測定した。一態様においては、国際公開第96/12697号の実施例4に記載の方法に従って測定を実施した。
体重250−400gの雄性スプレーグドーリーラットに食物及び水を自由に摂らせた。無麻酔のラットに18ゲージ球状(balled)針を用いて0.5から1mlの体積で食事を投与した。化合物を20%Captisol水溶液中でpH7.0で処方し、又は2%ヒドロキシプロピルメチルセルロース(HPMC)/1%Tween 80/5%Captisol水溶液中でpH2.0で処方した。カルシウム擬態薬を、20%Captisol中の0.03−30mg/kgの範囲の種々の用量で投与した。ビヒクルで処理したラットは、カルシウム擬態薬に用いた上記2種類のビヒクルの1つを最大体積(0.5−1ml)で投与された。0時(カルシウム擬態薬又はビヒクル投与前)及びカルシウム擬態薬又はビヒクルの強制経口投与後異なる時間(1、2、4、8及び24時間)で各ラットから採血した。
Claims (8)
- 式Iの化合物、又は薬学的に許容されるその塩。
R1は、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、フェニル、ベンジル、ナフチル又は複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロから選択される0、1、2又は3個の置換基で置換され、
R2はC1−8アルキル又はC1−4ハロアルキルであり、
R3はH、C1−4ハロアルキル又はC1−8アルキルであり、
R4はH、C1−4ハロアルキル又はC1−8アルキルであり、
R5は、独立に、各場合において、H、C1−8アルキル、C1−4ハロアルキル、ハロゲン、−OC1−6アルキル、−NRaRd、NRaC(=O)Rd、置換若しくは非置換ピロリジニル、置換若しくは非置換アゼチジニル、又は置換若しくは非置換ピペリジルであって、置換基は、ハロゲン、−ORb、−NRaRd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、シアノ、ニトロ、−NRaS(=O)nRc又は−S(=O)nNRaRdから選択することができ、
Lは、−NRaC(=O)−又は−NRaC(=O)ORc−であり、
Cyは、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、R6、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
R6は、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
Raは、独立に、各場合において、H、C1−4ハロアルキル、C1−6アルキル、C1−6アルケニル、C1−6アルキルアリール又はアリールC1−6アルキルであり、
Rbは、独立に、各場合において、C1−8アルキル、C1−4ハロアルキル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、フェニル、ベンジル、ナフチル又は複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロから選択される0、1、2又は3個の置換基で置換され、
Rcは、独立に、各場合において、C1−6アルキル、C1−4ハロアルキル、フェニル又はベンジルであり、
Rdは、独立に、各場合において、H、C1−6アルキル、C1−6アルケニル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、C1−6アルキル、フェニル、ベンジル、ナフチル及び複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロ、Rb、−C(=O)Rc、−ORb、−NRaRb、−C(=O)ORc、−C(=O)NRaRb、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc及び−S(=O)mNRaRaから選択される0、1、2、3又は4個の置換基で置換され、
mは1又は2であり、
nは1又は2である。) - RaがHである、請求項1に記載の化合物、又は薬学的に許容されるその塩。
- 式Iの化合物、又は薬学的に許容されるその塩。
R1は、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、フェニル、ベンジル、ナフチル又は複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロから選択される0、1、2又は3個の置換基で置換され、
R2はC1−8アルキル又はC1−4ハロアルキルであり、
R3はH、C1−4ハロアルキル又はC1−8アルキルであり、
R4はH、C1−4ハロアルキル又はC1−8アルキルであり、
R5は、独立に、各場合において、H、C1−8アルキル、C1−4ハロアルキル、ハロゲン、−OC1−6アルキル、−NRaRd、NRaC(=O)Rd、置換若しくは非置換ピロリジニル、置換若しくは非置換アゼチジニル、又は置換若しくは非置換ピペリジルであって、置換基は、ハロゲン、−ORb、−NRaRd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、シアノ、ニトロ、−NRaS(=O)nRc又は−S(=O)nNRaRdから選択することができ、
Lは、−NRdC(=O)NRd−又は−NRdC1−6アルキル−であり、
Cyは、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、R6、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
R6は、部分若しくは完全飽和若しくは不飽和5−8員単環式、6−12員二環式、又は7−14員三環式環構造であって、環構造は炭素原子で形成され、単環式の場合は1−3個のヘテロ原子、二環式の場合は1−6個のヘテロ原子、又は三環式の場合は1−9個のヘテロ原子を含んでいてもよく、環構造の各環は、C1−8アルキル、C1−4ハロアルキル、ハロゲン、シアノ、ニトロ、−OC1−6アルキル、−NRaRd、NRdC(=O)Rd、−C(=O)ORc、−C(=O)NRaRd、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc又は−S(=O)mNRaRdの1個以上の置換基で独立に置換されていてもよく、
Raは、独立に、各場合において、H、C1−4ハロアルキル、C1−6アルキル、C1−6アルケニル、C1−6アルキルアリール又はアリールC1−6アルキルであり、
Rbは、独立に、各場合において、C1−8アルキル、C1−4ハロアルキル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、フェニル、ベンジル、ナフチル又は複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロから選択される0、1、2又は3個の置換基で置換され、
Rcは、独立に、各場合において、C1−6アルキル、C1−4ハロアルキル、フェニル又はベンジルであり、
Rdは、独立に、各場合において、H、C1−6アルキル、C1−6アルケニル、フェニル、ベンジル、ナフチルであり、又はN、O及びSから選択される1、2若しくは3個の原子を含む飽和若しくは不飽和5若しくは6員複素環であって、該原子のうち2個以下はO及びSから選択され、C1−6アルキル、フェニル、ベンジル、ナフチル及び複素環は、C1−6アルキル、ハロゲン、C1−4ハロアルキル、−OC1−6アルキル、シアノ及びニトロ、Rb、−C(=O)Rc、−ORb、−NRaRb、−C(=O)ORc、−C(=O)NRaRb、−OC(=O)Rc、−NRaC(=O)Rc、−NRaS(=O)mRc及び−S(=O)mNRaRaから選択される0、1、2、3又は4個の置換基で置換され、
mは1又は2であり、
nは1又は2である。) - RdがHである、請求項3に記載の化合物、又は薬学的に許容されるその塩。
- 化合物が以下からなる群から選択される、請求項1〜4のいずれか一項に記載の化合物、又は薬学的に許容されるその塩:
(R)−N−(2−クロロ−5−((1−(3−クロロフェニル)エチルアミノ)メチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−フランカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1,3−ジメチル−1H−ピラゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−フェニルプロパンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)ベンズアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−メチル−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−ピリジンカルボキサミド、
フェニルメチル(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)カルバマート、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−2,5−ジメチル−1,3−オキサゾール−4−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−4−メチル−1,2,3−チアジアゾール−5−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−メチル−1,3−チアゾル−4−イル)−3−イソオキサゾールカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−N’−フェニル尿素、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−1−(1,1−ジメチルエチル)−5−メチル−1H−ピラゾール−3−カルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−3−イソオキサゾールカルボキサミド、
6−クロロ−N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−3−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−(2−ピリジニル)−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−5−フェニル−2−チオフェンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−(1−ナフタレニル)エチル)アミノ)メチル)フェニル)−2−ピリジンカルボキサミド、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−2−(ピロリジン−1−イル)アセトアミド、
(R)−N−(2−クロロ−5−((1−フェニルエチルアミノ)メチル)フェニル)−6−(ジメチルアミノ)ニコチンアミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−モルホリニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(4−メチル−1−ピペラジニル)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−(ジメチルアミノ)エチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(メチルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−(フェニルアミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((フェニルメチル)アミノ)−3−ピリジンカルボキサミド、
N−(2−クロロ−5−((((1R)−1−フェニルエチル)アミノ)メチル)フェニル)−6−((2−フェニルエチル)アミノ)−3−ピリジンカルボキサミド、
(R)−1−(2−(5−メチルイソオキサゾール−3−カルボキサミド)−4−((1−フェニルエチルアミノ)メチル)フェニル)ピペリジン−4−カルボキサミド、
(R)−2−クロロ−5−((1−フェニルエチルアミノ)メチル)−N−(ピリジン−2−イルメチル)ベンゼンアミン、
N−(2−クロロ−5−(1−((R)−1−(3−クロロフェニル)エチルアミノ)エチル)フェニル)−5−メチルイソオキサゾール−3−カルボキサミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−p−トリル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸{3−[((S)−1−フェニル−エチルアミノ)−メチル]−フェニル}−アミド、
チオフェン−2−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
チオフェン−2−カルボン酸{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−アミド、
5−メチル−イソオキサゾール−3−カルボン酸(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−アミド、
N−(3−{[(S)−1−(3−メトキシ−フェニル)−エチルアミノ]−メチル}−フェニル)−2−ピロリジン−1−イル−アセトアミド、
N−{3−[((S)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−2−ピロリジン−1−イル−アセトアミド、
及び
N−{2−メトキシ−5−[((R)−1−ナフタレン−1−イル−エチルアミノ)−メチル]−フェニル}−N−メチル−ベンズアミド。 - 請求項5に記載の化合物、又は薬学的に許容されるその塩と、薬学的に許容される希釈剤又は担体とを含む、薬剤組成物。
- 請求項1〜5のいずれか一項に記載の化合物、又は薬学的に許容されるその塩を含む、
高PTHレベルに関連する副甲状腺機能亢進症、高カルシウム血症又は慢性腎疾患血管石灰化、下痢、同化不良又は栄養失調を治療するための薬剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85490906P | 2006-10-26 | 2006-10-26 | |
US60/854,909 | 2006-10-26 | ||
PCT/US2007/022714 WO2008057282A1 (en) | 2006-10-26 | 2007-10-25 | Calcium receptor modulating agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010508269A JP2010508269A (ja) | 2010-03-18 |
JP5470653B2 true JP5470653B2 (ja) | 2014-04-16 |
Family
ID=39111874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009534673A Expired - Fee Related JP5470653B2 (ja) | 2006-10-26 | 2007-10-25 | カルシウム受容体調節剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8349831B2 (ja) |
EP (1) | EP2079525A1 (ja) |
JP (1) | JP5470653B2 (ja) |
AU (1) | AU2007318092B2 (ja) |
CA (1) | CA2672956C (ja) |
MX (1) | MX2009003981A (ja) |
WO (1) | WO2008057282A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010514839A (ja) | 2007-01-03 | 2010-05-06 | バーナム インスティテュート フォー メディカル リサーチ | クロット結合化合物に関連する方法および組成物 |
AU2008233088B2 (en) | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
EP2156846B1 (en) * | 2007-05-08 | 2014-08-13 | Ajinomoto Co., Inc. | Prophylactic or therapeutic agent for diarrhea |
MY167602A (en) * | 2007-11-01 | 2018-09-20 | Acucela Inc | Amine derivatives compounds for treating ophthalmic diseases and disorders |
MX2010010485A (es) * | 2008-03-28 | 2011-03-30 | Amgen Inc Star | Compuesto calcimimetico para su uso en el tratamiento de lesiones epiteliales. |
WO2010039911A1 (en) * | 2008-10-01 | 2010-04-08 | Glaxosmithkline Llc | Calcilytic compounds |
EP3725775A1 (en) | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- and pyrimidinecarboxamides as cxcr2 modulators |
JP2013515008A (ja) | 2009-12-18 | 2013-05-02 | サンフォード−バーナム メディカル リサーチ インスティテュート | 凝血塊結合化合物に関連する方法および組成物 |
AU2011293612B2 (en) | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
CA2829466A1 (en) * | 2011-03-18 | 2012-09-27 | Lupin Limited | Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators |
PE20142281A1 (es) * | 2012-02-24 | 2015-01-16 | Lupin Ltd | Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio |
AU2015402192B2 (en) | 2015-07-10 | 2021-06-10 | Infectopharm Arzneimittel Und Consilium Gmbh | Use of potassium hydroxide in the treatment of actinic keratosis |
WO2017037616A1 (en) * | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
CN108610246A (zh) * | 2018-06-01 | 2018-10-02 | 山东潍坊润丰化工股份有限公司 | 一种环丙唑醇中间体1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0188268A3 (de) | 1985-01-17 | 1990-01-31 | Alcoa Chemie GmbH | Verfahren zur Herstellung von Aluminiumhydroxid mit niedrigem Gehalt an Verunreinigungen, insbesondere an Eisen, und hohem Weissgrad |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
ATE287390T1 (de) | 1994-10-21 | 2005-02-15 | Nps Pharma Inc | Kalzium-rezeptor aktive verbindungen |
CZ20013046A3 (cs) | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | Fenylové a pyridinylové deriváty |
EP1074539B1 (en) | 1999-08-04 | 2007-10-17 | Sumitomo Chemical Company, Limited | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TW200528436A (en) * | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
EP1116711B1 (de) | 1999-12-18 | 2005-12-14 | Wella Aktiengesellschaft | 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel |
FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
JP4045722B2 (ja) * | 2000-07-19 | 2008-02-13 | 住友化学株式会社 | アミン化合物、中間体、製造法および光学分割剤 |
FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
EP1360173A2 (en) * | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
TW200412956A (en) | 2002-09-30 | 2004-08-01 | Schering Corp | Methods for treating disorders of calcium homeostasis |
PT1757582E (pt) | 2004-05-28 | 2016-03-04 | Mitsubishi Tanabe Pharma Corp | Arilalquilaminas e processo para a sua produção |
WO2008035381A2 (en) | 2006-09-22 | 2008-03-27 | Ind-Swift Laboratories Limited | Process for the preparation of amine derivatives as calcimimetics |
-
2007
- 2007-10-25 AU AU2007318092A patent/AU2007318092B2/en not_active Ceased
- 2007-10-25 WO PCT/US2007/022714 patent/WO2008057282A1/en active Application Filing
- 2007-10-25 MX MX2009003981A patent/MX2009003981A/es active IP Right Grant
- 2007-10-25 EP EP07861535A patent/EP2079525A1/en not_active Withdrawn
- 2007-10-25 JP JP2009534673A patent/JP5470653B2/ja not_active Expired - Fee Related
- 2007-10-25 US US11/977,777 patent/US8349831B2/en active Active
- 2007-10-25 CA CA2672956A patent/CA2672956C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2007318092A1 (en) | 2008-05-15 |
EP2079525A1 (en) | 2009-07-22 |
CA2672956C (en) | 2015-02-10 |
US20080221101A1 (en) | 2008-09-11 |
CA2672956A1 (en) | 2008-05-15 |
US8349831B2 (en) | 2013-01-08 |
MX2009003981A (es) | 2009-04-27 |
AU2007318092B2 (en) | 2013-01-10 |
WO2008057282A1 (en) | 2008-05-15 |
JP2010508269A (ja) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5470653B2 (ja) | カルシウム受容体調節剤 | |
US8334317B2 (en) | Calcium receptor modulating agents | |
US8765676B2 (en) | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | |
US7396958B2 (en) | Sulphonamide derivatives, their preparation and their therapeutic application | |
JP3149186B2 (ja) | 糖尿病および肥満の治療のための選択的β▲下3▼作用物質としての置換スルホンアミド | |
CN100406007C (zh) | 哮喘和过敏性炎症调节剂 | |
CN103772239B (zh) | 酰胺和脒衍生物和其用途 | |
US8791147B2 (en) | Calcium receptor modulating agents | |
JP2005511532A (ja) | 5’−カルバモイル−1,1−ビフェニル−4−カルボキサミド誘導体及びそのp38キナーゼ阻害薬としての使用 | |
JP2011528372A (ja) | α7ニコチン性アセチルコリンレセプターインヒビター | |
WO2006133926A1 (en) | Pyrazole derivates as cannabinoid receptor modulators | |
EA016948B1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
TW201043603A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
JP2007500716A5 (ja) | ||
JP2005508967A (ja) | p38キナーゼ阻害剤としてのビフェニルカルボン酸アミド誘導体 | |
JP2001502712A (ja) | 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト | |
JP2005509622A (ja) | 5’−カルバモイル−2’−メチル−1,1’−ビフェニル−4−カルボキサミド誘導体及びそのp38キナーゼ阻害薬としての使用 | |
JP2010501014A (ja) | 疾病の処置に有用な置換アセチレン化合物 | |
JP2007516284A (ja) | オピオイド受容体拮抗物質 | |
JP2007529523A (ja) | 肥満症を治療するためのオピオイド受容体拮抗物質としての4−(5−アミノメチル)−インドール−1−イルメチル)−ベンズアミド誘導体および関連化合物 | |
KR101070176B1 (ko) | Cb1에 길항 활성을 갖는 1h-파이라졸-3-아마이드계 화합물 또는 1h-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물 | |
MX2007015551A (en) | Benzamide derivatives and uses related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121127 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130228 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130524 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5470653 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |